Aminosteroids for the Treatment of a PTP1B Associated Disease

Abstract

This application is directed to the use of aminosteroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.

1 .- 9 . (canceled) 
     
     
         10 . A compound or pharmaceutically acceptable salt thereof selected from the group consisting of: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         11 . A pharmaceutical composition comprising the compound of  claim 10  and a pharmaceutically acceptable diluent or carrier. 
     
     
         12 . A method of treating a disorder in a mammal mediated by inhibition of protein tyrosine phosphatase PTP1B comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of  claim 10  or a pharmaceutically acceptable salt thereof. 
     
     
         13 . The method of  claim 12 , wherein the disorder is selected from the group consisting of diabetes, obesity, high serum cholesterol, sleep apnea and nonalcoholic steatohepatitis. 
     
     
         14 . A compound of formula 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein: 
         R 1 =—NH(CH 2 ) 1-4 —NH—R 6 , H, 
       
       
         
           
           
               
               
           
         
         R 6 =—(CH 2 ) 1-4 —NH—R 7  or —(CH 2 ) 0-3 —C 1 -C 5  alkyl or —(CH 2 ) 0-3 —C 3 -C 7 cycloalkyl or —(CH 2 ) 0-3 —C 3 -C 6  heterocycloalkyl or —(CH 2 ) 0-3 -aromatic or —(CH 2 ) 0-3 -heteroaromatic or H; 
         R 7 =—(CH 2 ) 1-4 —NH 2  or —(CH 2 ) 1-4 —NH—(C 1 -C 5  alkyl) or —(CH 2 ) 1-4 —NH—(C 3 -C 6  heterocycloalkyl) or —(CH 2 ) 1-4 —NH-aromatic or —(CH 2 ) 1-4 —NH-heteroaromatic or H; 
         R 2 =—OH or H; 
         R 3 =—OH or NH—R 8  or methylsulfone or methyl sulfide or H; 
         R 8 =acetyl, —SO 2 —CH 3  or —C(O)OCH 3 ; 
         R 4 =—OH or H; and 
       
       
         
           
           
               
               
           
         
       
     
     
         15 . A compound of formula 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein: 
       
       
         
           
           
               
               
           
         
         X 2 =—OH or H; 
         X 3 =H, —OH, —S(O) 2 —CH 3 , —NHC(O)—CH 3 , —NHC(O)—OCH 3 , —NHC(O)—SCH 3 , —NH—SO 2 CH 3  or —SCH 3 ; 
         X 4 =—OH or H; and 
         X 5 =H or —CH 3 . 
       
     
     
         16 . A compound of formula 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein: 
       
       
         
           
           
               
               
           
         
         X 2 =—OH or H; 
         X 7 =—OH or H; 
         X 4 =—OH or H; and 
         X 8 =—OH or H. 
       
     
     
         17 . A pharmaceutical composition comprising the compound of  claim 14  and a pharmaceutically acceptable diluent or carrier. 
     
     
         18 . A method of treating a disorder in a mammal mediated by inhibition of protein tyrosine phosphatase PTP1B comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of  claim 14 , or a pharmaceutically acceptable salt thereof. 
     
     
         19 . The method of  claim 18 , wherein the disorder is selected from the group consisting of diabetes, obesity, high serum cholesterol, sleep apnea and nonalcoholic steatohepatitis. 
     
     
         20 . A pharmaceutical composition comprising the compound of  claim 15  and a pharmaceutically acceptable diluent or carrier. 
     
     
         21 . A method of treating a disorder in a mammal mediated by inhibition of protein tyrosine phosphatase PTP1B comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of  claim 15  or a pharmaceutically acceptable salt thereof. 
     
     
         22 . The method of  claim 21 , wherein the disorder is selected from the group consisting of diabetes, obesity, high serum cholesterol, sleep apnea and nonalcoholic steatohepatitis. 
     
     
         23 . A pharmaceutical composition comprising a compound of  claim 16  and a pharmaceutically acceptable diluent or carrier. 
     
     
         24 . A method of treating a disorder in a mammal mediated by inhibition of protein tyrosine phosphatase PTP1B comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of  claim 16 , or a pharmaceutically acceptable salt thereof. 
     
     
         25 . The method of  claim 24 , wherein the disorder is selected from the group consisting of diabetes, obesity, high serum cholesterol, sleep apnea and nonalcoholic steatohepatitis.